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I am pleased to be writing this endorsement on behalf of Christin Pramudiati. 
Her submission for publication in Kaleidoscope is original research that she 
completed within my laboratory in collaboration with Dr. Razvan Arsenescu 
(Internal Medicine, Gastroenterology).  Christin is an exceptional student whose 
meticulous methods and outstanding work ethic in the laboratory have separated 
her from her peers.  The specific research presented in this submission is novel 
and has led to a patentable technology that promises to have application in the 
controlled delivery of therapeutic agents from degradable Setons.
Razvan Arsenescu, M.D.
Assistant Professor, Gastroenterology, 
College of Medicine
I   just graduated with my bachelors degree in Chemi-  cal  Engineering this past May.  I am originally from Indonesia, and my journey in the University of Kentucky 
started in Spring, 2001.  During my studies, I was a runner-
up in the Physical and Engineering Sciences category of the 
2006 Oswald Research and Creativity Program.  Also, I was 
member of Tau Beta Pi, the Engineering Honor Society, and 
the American Institute of Chemical Engineers (AIChE).  In 
the Summer of 2005, the Nanoscale Engineering Certificate 
Program (NECP) granted me a summer fellowship that has partially supported 
the research reported here.
Based on my two previous research experiences and my future plan to 
attend graduate school in Pharmaceutical Science, I was looking for another 
research opportunity after I came back from my co-op, a year-long internship 
at ISP Chemical Inc., Calvert City, KY.  At that time, a new faculty member in 
the department of Chemical and Material Science, Dr. J. Zach Hilt, offered me 
an opportunity to take part in his joint project with Dr. Razvan Arsenescu in the 
department of Internal Medicine and Gastroenterology.  The project involves 
developing a polymer-based (PLGA) drug delivery system for Crohn’s disease. 
Through support from my mentors and the continuation of this project, I was 
able to work on this research independently for one and a half years and also 
obtain a strong foundation for the drug delivery–­focused PhD program in Phar-
maceutical Science that I am about to pursue in Fall, 2006.  Moreover, from the 
preliminary data obtained during this research, we are currently in the process 
of filing a patent application on this novel device.
Outside of my books, I enjoy playing musical instruments, but mostly 
keyboard.  During the school year, I usually play keyboard at the International 
Christian Fellowship (ICF).  Besides being a worship leader in ICF, I am also 
involved with lots of other activities that are oriented mostly to international 
students.  These activities include but are not limited to serving as secretary 
for the International Student Council in 2002-2003 and volunteering in several 
welcome weeks, activities that are put together to welcome new international 
students who have just arrived on campus.
Abstract
The purpose of this research is to develop biode-
gradable drug delivery systems.  One of the deliv-
ery systems that we have developed is a suture-like 
structure for the treatment of Crohn’s disease that 
utilizes a biodegradable polymer, poly(DL-lactide-
co-glycolide) acid (PLGA).  Crohn’s disease is an 
inflammatory bowel condition.  Aside from the 
gut involvement, perianal complications develop 
in the form of enterocutaneous fistulas.  Medical 
management of Crohn’s disease consists of vari-
ous drugs with immunosuppressive properties. 
Complicated disease manifestation requires surgi-
cal interventions in the form of bowel resection or 
fistula drainage with Setons.  Setons are suture-like 
devices that help to drain associated abscesses and 
close secondary fistulous tracts.  They are often 
removed prematurely to prevent entrapment as 
the proximal and distal ends of the fistula heal. 
In their current form, Setons are not degradable 
and are not able to deliver drugs.  Thus, the pa-
tients typically receive their drugs systemically. 
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Figure 2.  
Seton placed in a perianal fistula       
Figure 1.  
Types of 
fistulas based 
on anatomical 
locations
The novel device, biodegradable Setons from PLGA, 
that we developed promises superior treatment by 
providing adequate drainage, uniform healing, and a 
lower level of immunosupression.  Currently, there is 
a patent application filed on this novel device.
The chronic inflammation is driven by cells of 
the innate and acquired immune system.  Macro-
phages and dendritic cells (innate immune system 
cells) sample luminal (gut) antigens and trigger more 
specialized acquired immune responses.  Targeting 
these cells may break a vicious cycle that creates a 
chronic state of inflammation within the gut.  Drug 
incorporated-biodegradable nanoparticles can mimic 
inert particulate matter present in the lumen of the 
gut.  Thus, they may be actively sampled by dendritic 
cells.  Most of these cells remain within the lamina 
propria of the gut or travel to the gut-associated lymph 
nodes.  By targeting these antigen-presenting cells, we 
anticipate preventing ongoing activaction of B and T 
cells (acquired immunity) and limiting the systemic 
exposure to immunosuppressive drugs.
These innovative methods present a more effi-
cient and safe drug delivery that addresses both the 
chronic gut inflammation (via nanoparticles) and the 
associated perianal complications (via Setons).
1.   Introduction
1.1.  Crohn’s Disease
Crohn’s disease is an inflammatory bowel disease 
that results from a deregulated immune response to 
the commensal intestinal flora.  Aside from the gut 
involvement, perianal complications develop in the 
form of enterocutaneous fistulas.  Medical manage-
ment of Crohn’s disease consists of various drugs 
with immunosuppressive properties.  Complicated 
disease manifestations require surgical interventions 
in the form of bowel resection or fistula drainage 
with Setons.
The cumulative frequency of perianal fistulas in 
patients with Crohn’s disease has been reported to 
range from 14% to 38% in referral centers [1], with 
17% to 28% of patients requiring surgery [2].  For 
treatment of the fistulas, Tacrolimus and Infliximab 
are the only drugs shown to be effective in prospec-
tive, randomized, placebo-controlled studies.  The 
former can be used orally and topically.  In addition 
to side effects associated with large dose administra-
tions, recurrence after treatment cessation is a major 
problem with both drugs.  In other cases, anatomi-
cally complex and medication refractory fistulas re-
quire surgical treatment.  Continuous drainage with 
surgically placed Setons (see Figure 1 and 2), is an 
effective, less invasive, complementary, or stand-alone 
management.  However, for treatment with current 
Setons, the caveats are patient discomfort, associated 
with long term placement of these non-resorbable 
sutures, and absence of complete closure.
Therefore, creating a drug eluting, biodegradable 
Seton from a PLGA system promises great benefits: (i) 
the incorporated drug will be slowly and continuously 
released over time while providing targeted delivery of 
a lower dose, (ii) uniform healing, because the Seton 
will be present in the fistulous tract even after the 
distal and proximal ends (see Figure 2) have closed, 
(iii) Seton entrapment is no longer an impediment, 
given the biodegradable nature of these polymers. 
Overall, this novel device will translate to long-lasting 
therapeutic success, improved safety, and quality of 
life for these patients.
1.2.  Poly (DL-Lactic-Glycolic) Acid (PLGA)
There has been a great amount of research conducted 
on controlled drug delivery using biodegradable 
polymer systems.  Compared to other biodegrad-
able polymers, poly (D,L-lactide-co-glycolide) acid 
(PLGA) systems, copolymers of poly(lactic acid) 
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Figure 3.  Chemical 
Structure of PLGA  
Figure 4.  
Half–life of PLA and PGA 
(Adapted from Reference [4])
(PLA) and poly(glycolic acid) (PGA), have gener-
ated great interest due to their favorable properties, 
including excellent biocompatibility, biodegradability, 
and mechanical strength.  Also, PLGA systems have 
been approved by the Food and Drug Administration 
(FDA) for use in drug delivery applications.  PLGA 
is advantageous because it biodegrades into lactic 
and glycolic acids, which can then be metabolized 
and eliminated from the body as carbon dioxide and 
water [3].        
The degradation of PLGA systems is dependent 
on their physical properties (i.e., the molecular weight 
and polydispersity index) and molar ratio of the indi-
vidual monomer components (lactide and glycolide) 
(see Figure 3) in the copolymers [3].  PLGA polymers 
with a 50:50 ratio of lactic acid and glycolic acids 
are hydrolyzed much faster than those containing a 
higher ratio of either monomer [4] (see Figure 4).  
For degradation analysis purposes, we are mainly 
focusing on three different ratios of PLGA: 75:25, 
65:35, and 50:50.  From figure 4, it can be seen that 
within the range of PLA ratios from 50% to 100%, 
copolymers with higher ratios of lactide exhibit a 
higher half-life, thus degrading more slowly.  There-
fore, as expected, PLGA with a ratio of 50:50 degrades 
first, followed by 65:35 and 75:25.  Degradation of 
this biodegradable polymer results in a mass loss 
due to the resorption or dissolution of the material, 
accompanied by a reduction in molecular weight and 
changes in mechanical properties such as strength 
and stiffness.  
1.3.  PLGA Nanoparticles
The chronic inflammation of Crohn’s disease is driven 
by cells of the innate and acquired immune systems. 
Macrophages and dendritic cells (innate immune 
system cells) sample luminal (gut) antigen and trig-
ger more specialized acquired immune responses. 
The significant roles that macrophages and dendritic 
cells play in the regulation of immune responses in 
the gastrointestinal tract as antigen-presenting cells 
are well known [5,6,7].  Targeting these cells may 
break a vicious cycle that creates a chronic state of 
inflammation within the gut [8] .  Drug eluting, bio-
degradable nanoparticles, can mimic inert particulate 
matters present in the lumen of the gut.  Thus, they 
may be actively sampled by dendritic cells.  Most 
of these cells remain within the lamina propria of 
the gut or travel to the gut associated lymph nodes. 
By targeting these antigen-presenting cells, we can 
prevent the ongoing activation of B and T cells (ac-
quired immunity) and limit the systemic exposure of 
immunosuppressive drugs.
In order to target these specific cells, the drug delivery system needs 
to be designed in the nanoscale range.  Particles that are less than 500 
nm can cross the microfold (M) cells in the Payer’s patch or be actively 
sampled by dendritic cells [9].  Therefore, based on the previous research 
of Tabata [10,11,12,13] and Nakase [8] that has proven the efficient 
uptake of microparticles by activated macrophages, we attempted to 
tailor a controlled drug release from PLGA nanoparticles with size of 
less than 1m.  
PLGA nanoparticles were obtained by using an oil-in-water emul-
sion method.  With the help of a surfactant, polyvinyl alcohol (PVA), 
and stirring the emulsion at about 7900 rpm for 2 minutes, 150-250 nm 
particles can be obtained by using acetone as the solvent.  The size of 
the nanoparticles acquired depends on several different variables, in-
cluding (i) solvent choice, (ii) PLGA concentration in the solvent, (iii) 
the concentration, volume, and type of surfactant, (iv) the volume ratio 
of PLGA and surfactant, and (v) speed of stirring.  
1.4.  Polyphenols (Green Tea)
Green tea polyphenols are natural plant antioxidants found in tea leaves. 
Much research has been done to prove that antioxidants can prevent 
damage caused by free radicals to DNA and other molecules [14].  In 
addition to several cancer preventive properties, these compounds may 
reduce abnormal cell growth and inflammation, free the body from 
cancer causing agents, and restore communication between different 
cells in the body.  Green tea polyphenols have also been shown to be 
effective in murine models of Crohn’s disease.  Polyphenols were used 
as a model drug system in these experiments.
2.    Experimental Method
2.1.  Preparation of the PLGA films
Three ratios of PLGA films were prepared by casting a solution of PLGA 
(75:25, 65:35, or 50:50) and acetone into either aluminum or Teflon 
molds.  Films were dried for at least 48 hours before being peeled and 
circled with a cork borer into discs with an average diameter of 8.4 
mm (see Figure 5).  Films with different thicknesses were obtained by 
dissolving PLGA with acetone.  Drug-loaded PLGA films with different 
ratios (75:25, 65:35, and 50:50) were prepared in a similar manner.  
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Figure 5.  
Preparation of PLGA film without drug incorporated.  When drug 
needs to be incorporated, it can be added to the system once the 
polymer has dissolved.
Figure 6.  
Degradation study of PLGA system using mass loss analysis
2.2.  Degradation Study
A degradation study of different ratios was carried out by analyzing the 
mass loss of PLGA discs at six time points: 1, 2, 3, 4, 6, and 8 weeks, 
and that of different thickness of PLGA film done with 10 time points. 
For error analysis, samples were prepared in triplicate.  PLGA discs were 
immersed in PBS (Phosphate Buffered Saline) (see Figure 6).  At each 
time point, discs were taken from the water bath for mass analysis, while 
the PBS in the remaining samples was replaced weekly with fresh PBS. 
The mass of the discs at the various time points was then compared to 
their initial mass.  Then, the degradation (mass at time point divided 
by initial mass) was calculated.  
2.3.  Quantification of Polyphenols’ 
Concentration
Prior to calibration, solutions of green tea polyphe-
nols and PBS pH 7.4 were prepared in various con-
centrations: 0.0005, 0.001, 0.005, 0.010, and 0.015 
mg/ml.  Calibration was carried out by measuring 
the absorbance of each concentration in a UV-Vis-
ible Spectrophotometer over the wavelength range 
of 200 to 250 nm.  Polyphenols have their strongest 
absorbance at 207 nm.  
2.4.  Drug Release Study
Discs loaded with the drug were immersed in PBS. 
Samples for each ratio of PLGA (75:25, 65:35, and 
50:50) were prepared in quadruplicate.  For infinite 
sink conditions, the PBS solution in each vial was 
replaced at each time point with a fresh solution.  The 
absorbance of each solution was measured using a 
UV-Visible Spectrophotometer at 207 nm.  Then, the 
absorbance data was translated to the concentration 
by using the calibration curve.  
2.5.  PLGA Nanoparticles
Currently, the most optimized nanoparticles were 
obtained by the following method: PLGA was dis-
solved in acetone in a centrifuge tube.  If polyphenols 
or another compound was to be encapsulated, it 
was added after the polymer was dissolved.  To this 
solution, a surfactant, poly(vinyl alcohol) (PVA), was 
added, and the resulting emulsion was very briefly 
hand shaken before being homogenized.  The emul-
sion was then transferred to a vacuum with additional 
water used as a rinse.  To remove the residual acetone, 
the emulsion was stirred while under a modest 
vacuum.  While stirring continued, a small volume 
of emulsion was removed from the flask for sizing. 
All the materials used in the procedure were simply 
multiplied proportionally by a factor of 1/4, 1/2, 2, 
5, etc, to obtain various quantities of nanoparticles. 
To remove the drug present in the surfactant, the 
nanoparticles were separated using centrifugation. 
The supernatant was collected and analyzed using a 
UV Visible spectrophotometer (at 207 nm) to detect 
the amount of polyphenols that was not encapsulated 
in the nanoparticles.  The pellets of nanoparticles 
were combined and re-suspended in PVA solution 
for release study purposes.  Currently, we are still in 
the process of developing a better, more efficient way 
to synthesize these nanoparticles and to evaluate the 
polyphenols released from this system.  
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Figure 8.  
Degradation 
of PLGA 
50:50 (I.V.: 
0.58) with 
three different 
thicknesses by 
mixing PLGA 
(1, 2.5, and 5 
g) and acetone 
at 10% w/w, 
N=3
Figure 9.  
Correlation 
between 
concentration 
of polyphenols 
and absorbance, 
described by 
Beer’s Law
Table 1.  Summary of particle average size and the standard 
deviation due to the effects of various variables
Figure 7.  
Degradation of 
three different 
ratios of PLGA 
(75:25, 65:35, 
and 50:50), 
N=3
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3.  Results and Discussion
3.1.  Degradation Study of Different Ratios of PLGA
The degradation and drug release of PLGA varies 
depending on the ratio of the PLA to PGA.  The 50:50 
ratio starts to degrade in 2 weeks, followed by 65:35 
and 75:35.  Often, we performed molecular weight 
analyses instead of mass loss analyses to obtain a 
more accurate degradation study.  However, because 
this research was conducted with a target of in vivo 
drug delivery, mass loss analysis can give a good rep-
resentation of the degradation and a rough estimation 
of the residence time of the system in the body.  To 
obtain a preliminary estimate of the PLGA degrada-
tion in vitro, we carried out the study using the PLGA 
discs.  Wu et al. [15] reported the study of various 
ratios of PLGA in the form of rods.  The difference in 
the geometries (between discs and rods) might give 
a slightly different degradation response.  However, 
an in vivo study using Seton-like structures is being 
planned to be carried out in the near future.  Thus, 
more accurate degradation of PLGA and its inflam-
matory response will be studied further.  
The summary of the preliminary PLGA degrada-
tion study based on different ratios is presented in 
Figure 7.  The relatively large error bars associated 
with the figures were caused by several factors, 
including variance of PLGA weight percent in the 
system and mass loss during solution replacement 
in the experimental methods.  The use of a filter and 
mesh could be a way to reduce the error.  Also, by 
making larger PLGA films, all the discs used for the 
experiment will be somewhat more homogenous, 
thus, decreasing the error.  
3.2.  Degradation Study of Different Thicknesess 
of PLGA Film
Figure 8 indicates that the degradation of PLGA also 
varies depending on the thickness of the film.  The 
thicker PLGA film degrades a lot faster compared to 
the thin one.  This is due to the fact that the thicker 
PLGA film tends to lower the pH of the media, causing 
the film to be even easier to degrade.  Due to difficul-
ties in handling and weighing the discs, large errors 
were generated with the thinnest film.  
3.3.  Quantification of Polyphenols Concentration
Figure 9 shows the correlation between the concen-
tration of the polyphenols and their absorbances, 
obtained from a UV-Visible spectrophotometer.  The 
absorbance data used was normalized at 207 nm, 
where polyphenols absorbance is at its maximum. 
By determining the absorbance of five different con-
centrations (listed in section 2.2), the constant value 
of eb, 169.49, can be obtained from the linear plot, 
Figure 10.  
Polyphenols 
release rate 
from 3 different 
ratios of PLGA, 
N=4
Figure 11.  
Particle 
analyzer result: 
nanoparticles 
size taken right 
after being 
homogenized
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following Beer’s law.  In the release study, the poly-
phenols incorporated in the discs were slowly released 
to the PBS solution in which they were incubated.  At 
its time point, the absorbance of these PBS solutions 
was measured using a UV-Visible Spectrophotometer. 
Thus, by utilizing the attained eb value, the only un-
known variable, concentration (c), can be calculated 
from the measured solution absorbance (A) .
3.4.  Release Study
From the release study data summary (see Figure 
10), it can be seen that the release of drug is directly 
related to the physical properties of the PLGA system. 
Here, the ratio of the mass released at time t, Mt, over 
mass released at time infinity, Minf, is plotted versus 
time.  The PLGA with a ratio of 50:50 released the 
polyphenols first, followed by 65:35 and 75:25.  Using 
this release data, we can possibly tailor the release of 
the drug in a similar dosage over a period of up to 4 to 
5 months.  The errors in the release study data were 
partially generated by the inhomogeneous distribu-
tion of polyphenols in the PLGA films, which results 
in a slightly different loading concentration in each 
disc being studied. 
3.5.  Nanoparticles
Table 1 shows some values of the particle average 
size along with standard deviations due to the com-
binations of different variables.  There are many 
factors that determined the size of the nanoparticles, 
including: the ratio of the PLGA over the surfactant, 
the amount of PLGA in the solvent, concentration 
and volume of the surfactant, homogenizing time 
and speed, solvent and surfactant choices, and many 
more.  By utilizing acetone as the solvent to dilute the 
PLGA and PVA as the surfactant, the smallest size of 
particles obtained during experiments were from a 
ratio volume of PLGA and PVA of 3:5.  At this volume 
ratio, nanoparticles with the size of 150-250 nm have 
been successfully synthesized.  
Figure 11 shows the size of the particles, 202.15 
± 41.9 nm, that were used for the release study.  The 
size of the particles was confirmed using a scanning 
electronic microscope (Figure 12).  The “strings” 
observed in Figure 12 were most probably formed 
due to excessive PVA that still had not been removed 
from the system.  PVA was kept in the system to 
avoid particles aggregating.  Again, we are in the 
process of developing a better, more efficient method 
to synthesize these nanoparticles, and the release 
study of nanoparticles still also needs to be further 
developed.
4.  Conclusions
Through this research, we have successfully devel-
oped a degradable Seton from PLGA that also will 
be able to release drugs locally.  Because the PLGA 
degradation rate in any form of device can be tailored 
based on its dependency on the physical properties, 
such as ratio, molecular weight, and polydispersity 
index, this device promises a better therapeutic system 
for Crohn’s disease patients.  With these preliminary 
experiments, we were able to determine the degrada-
tion rate of the PLGA at different ratios (75:25, 65:35, 
and 50:50) and thicknesses using mass loss analysis. 
Although there were errors associated with the mass 
loss analysis, trends were observed.  The release of 
polyphenols in PLGA discs with different ratios was 
quantified using the calibration data obtained.  A 
Phase I clinical study for patients with fistulizing 
Crohn’s disease is in the process of being developed. 
We are also attempting to optimize the nanoparticle 
production and ways to analyze the release of a model 
drug (e.g.,  polyphenols).  Overall, we believe that 
these drug delivery methods present a more efficient 
and safe drug delivery that addresses both the chronic 
gut inflammation (via nanoparticles) and the associ-
ated perianal complications (via Setons).
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Figure 12.  
Scanning 
electron 
microscope 
image of 
nanoparticles
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